Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2951 to 3000 of 3761 results for treatment

  1. Further collection of quality of life data from people who are cured and who have experience of amputation and chemotherapy are also needed. Additional data on the health effects on parents, siblings and others with life-threatening illness would also be of value.

    Source guidance details Comes from guidance Mifamurtide for the treatment of osteosarcoma Number TA235 Date issued October 2011

    Research recommendation
    Published
    9 June 2015

  2. Research is needed to generate robust and relevant data on the effects of treating people with Alzheimer's disease on both short-term and long-term outcomes, disease progression through relevant health states, and quality of life.

    guidance Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Number TA217 Date issued March

    Research recommendation
    Published
    9 June 2015

  3. People who are concerned about their fertility should be informed that the effectiveness of complementary therapies for fertility problems has not been properly evaluated and that further research is needed before such interventions can be recommended. [2004]

    details Comes from guidance Fertility problems: assessment and treatment Number CG156 Date issued February 2013 Other

    Research recommendation
    Published
    9 June 2015

  4. A trial comparing the long-term effectiveness (beyond 24 weeks) of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate and placebo would be beneficial. It should collect utility data as well as walking distance outcomes.

    naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral...

    Research recommendation
    Published
    9 June 2015

  5. The Committee recommends that a study estimating utility values using directly observed health-related quality of life values (such as EQ 5D scores) in patients with myelodysplastic syndromes, chronic myelomonocytic leukaemia or acute myeloid leukaemia is conducted.

    Source guidance details Comes from guidance Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia...

    Research recommendation
    Published
    9 June 2015

  6. The Committee considered that rigorous data collection is needed on the life-extending benefits of lenalidomide when used in people with multiple myeloma who have received two or more prior therapies.

    guidance details Comes from guidance Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior...

    Research recommendation
    Published
    25 October 2019

  7. Investigations for babies who may have early-onset infection: What is the clinical and cost effectiveness of laboratory investigations used individually or in combination to exclude early-onset neonatal infection in babies receiving antibiotics for suspected infection?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  8. What is the effect of dietary interventions or dietary changes on acne?

    committee's discussion are in evidence review C: dietary interventions for the treatment of acne vulgaris. Source guidance details Comes...

    Research recommendation
    Published
    3 May 2024

  9. Diet: What is the effect of dietary interventions or dietary changes on acne?

    committee's discussion are in evidence review C: dietary interventions for the treatment of acne vulgaris. Source guidance details Comes...

    Research recommendation
    Published
    10 August 2021

  10. The use of autologous chondrocyte implantation for the treatment of cartilage defects in the knee joints (TA89)

    This guidance has been updated and replaced by NICE technology appraisal guidance 477. 

    Withdrawn guidance

  11. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Withdrawn guidance

  12. Complex PTSD:- What is the clinical and cost effectiveness of interventions to deliver stabilisation and reintegration for people with complex PTSD?

    psychological, psychosocial and other non-pharmacological interventions for the treatment of PTSD in adults. Source guidance details...

    Research recommendation
    Published
    13 February 2019

  13. Intrapartum antibiotics: What is the clinical and cost effectiveness of intrapartum antibiotics for women with meconium-stained amniotic fluid?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  14. What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    about how this affects cost of the quality of life of patients receiving treatment. Source guidance details Comes from guidance...

    Research recommendation
    Published
    26 October 2020

  15. What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris?

    recommendation for research, see the rationale section on oral isotretinoin treatment . Full details of the evidence and the committee's...

    Research recommendation
    Published
    3 May 2024

  16. Guide to the processes of technology appraisal (PMG19)

    This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes

  17. Intrauterine laser ablation of placental vessels for the treatment of twin-to-twin transfusion syndrome (IPG198)

    We have moved interventional procedures guidance 198 to become HealthTech guidance 126. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  18. Multiple pregnancy: twin and triplet pregnancies (QS46)

    This quality standard covers the additional antenatal care for women who are pregnant with twins or triplets that is offered alongside routine antenatal care. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    4 September 2019
    View quality statements

    Sections for QS46

  19. Surveillance strategies: How frequently should surveillance imaging be conducted, and which imaging modality should be used for people with stage IIB to IIIC melanoma?

    recommendation for research, see the rationale and section on follow-up after treatment for melanoma. Full details of the evidence and...

    Research recommendation
    Published
    4 August 2022

  20. Oesophagectomy: What is the effectiveness of endoscopic resection with or without adjuvant chemoradiotherapy and oesophagectomy for adults with T1b oesophageal adenocarcinoma?

    committee's discussion are in evidence review K: oesophagectomy versus endoscopy treatment. Source guidance details Comes from guidance...

    Research recommendation
    Published
    9 March 2023

  21. Impact of neonatal infection on the baby's family: What is the impact of neonatal infection on the health-related quality of life of the baby's family?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  22. Survivorship: What are the experiences of people who are living with, through and beyond a melanoma diagnosis in terms of survivorship and their disease journey?

    recommendation for research, see the rationale and section on follow-up after treatment for melanoma. Full details of the evidence and...

    Research recommendation
    Published
    4 August 2022

  23. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    In development Reference number: GID-TA10843 Expected publication date: TBC

    Technology appraisal guidance
    In development

  24. Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure (IPG711)

    We have moved interventional procedures guidance 711 to become HealthTech guidance 599. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  25. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)

    This guidance has been updated and replaced by NICE technology appraisal guidance 784.

    Withdrawn guidance

  26. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Withdrawn guidance

  27. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.

    Withdrawn guidance

  28. Blood pressure targets for people aged over 80: What is the optimum blood pressure target for people aged over 80 with treated primary hypertension (with or without cardiovascular disease)?

    the committee's discussion are in the evidence review K: pharmacological treatment in cardiovascular disease . Source guidance details...

    Research recommendation
    Published
    11 April 2022

  29. During this appraisal it was noted that there is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.

    rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents. Any...

    Research recommendation
    Published
    10 August 2021

  30. Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTG759)

    Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards.

    HealthTech guidance
    Published
    27 August 2025
    View recommendations

    Sections for HTG759

  31. Autism spectrum disorder in adults: diagnosis and management (CG142)

    This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.

    Clinical guideline
    Last updated
    14 June 2021
    View recommendations

    Sections for CG142

  32. Risk factors for and clinical indicators of early-onset infection: What is the risk of early-onset neonatal infection with maternal obesity and how does this change with increasing body mass index?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  33. Endovascular stent insertion for intracranial atherosclerotic disease should only be used in the context of research. Research should clearly define patient selection and be designed to provide outcome data based on follow-up of at least 2 years.

    no substantial differences in clinical outcomes compared with medical treatment after 1–2 years. Evidence on its safety shows that there...

    Research recommendation
    Published
    9 June 2015

  34. Impact of drug-related adverse effects on cost effectiveness and quality of life:- What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    about how this affects cost of the quality of life of patients receiving treatment. Further research should be conducted as described...

    Research recommendation
    Published
    9 June 2015

  35. Intravascular catheters for reducing the risk of late-onset neonatal infection: What is the effectiveness of catheters impregnated with silver zeolite for preventing late-onset catheter-related bloodstream infections in newborn babies?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  36. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

    NICE guideline
    Published
    21 March 2024
    View recommendations

    Sections for NG241

  37. Medication choice in people with no previous medication for ADHD:- What is the clinical and cost effectiveness of ADHD medications in people with ADHD with noprevious medication for the condition?

    diagnosed ADHD.There may be differing levels of efficacy of the various treatment options in people who have received no previous...

    Research recommendation
    Published
    14 November 2018

  38. Specialist investigation:- What specialist investigations should be conducted to exclude a diagnosis of functional dyspepsia in people with uninvestigated dyspepsia that does not respond to PPIs or H2 receptor antagonists (H2RAs) despite optimum primary care?

    correct diagnosis or to correct misdiagnosis, so that the most appropriate treatment can be offered. Source guidance details Comes from...

    Research recommendation
    Published
    9 June 2015

  39. Intravascular catheters for reducing the risk of late-onset neonatal infection: What is the effectiveness of antimicrobial-impregnated catheters other than those impregnated with rifampicin and miconazole for preventing late-onset catheter-related bloodstream infections in newborn babies?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  40. Risk factors for and clinical indicators of early-onset infection: What is the accuracy of clinical prediction models for early-onset neonatal infection in the UK and what is their effectiveness in guiding management in the baby?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  41. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

    Medtech innovation briefing
    Published
    29 March 2022

  42. Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)

    Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making

    Medtech innovation briefing
    Published
    28 June 2016

  43. Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211]

    In development Reference number: GID-TA11201 Expected publication date:  26 February 2026

    Technology appraisal guidance
    In development

  44. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  45. Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine (TA53)

    This guidance has been replaced by NICE guideline NG17.

    Withdrawn guidance

  46. For people with generalised anxiety disorder (GAD) who are ready to start a low-intensity intervention, what is the clinical effectiveness of physical activity compared with waiting-list control?

    of this study will have important implications in widening the range of treatment options available in the NHS. Source guidance details...

    Research recommendation
    Published
    9 June 2015

  47. Interventions to improve CPAP adherence: Which interventions, including behavioural interventions, are most clinically and cost effective to improve adherence to CPAP in people with OSAHS, obesity hypoventilation syndrome (OHS) and COPD–OSAHS (chronic obstructive pulmonary disease–OSAHS) overlap syndrome who have difficulty using CPAP?

    recommendation for research, see the rationale section on supporting adherence to treatment for OSAHS. Full details of the evidence and...

    Research recommendation
    Published
    30 September 2021

  48. Psychotic symptoms (hallucinations and delusions):- What is the effectiveness of rivastigmine compared with atypical antipsychotic drugs for treating psychotic symptoms (particularly hallucinations and delusions) associated with Parkinson's disease?

    to undertake primary research in this area to determine the most effective treatment options formanaging Parkinson's disease psychosis....

    Research recommendation
    Published
    15 October 2018

  49. Risk factors for and clinical indicators of late-onset infection: What is the accuracy of new or existing clinical prediction models for late-onset neonatal infection in the UK and what is their effectiveness in guiding management: - for babies already on a neonatal unit? - for babies admitted from home?

    from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195 Date issued April 2021 Other details

    Research recommendation
    Published
    6 August 2021

  50. What specialist investigations should be conducted to exclude a diagnosis of functional dyspepsia in people with uninvestigated dyspepsia that does not respond to PPIs or H 2   receptor antagonists (H 2 RAs) despite optimum primary care?

    correct diagnosis or to correct misdiagnosis, so that the most appropriate treatment can be offered. Source guidance details Comes from...

    Research recommendation
    Published
    15 November 2019